Approved Parkinson’s treatment wins OK in EU, to be sold as Hopledo
The decision, by the European Commission, was based in large part on trial data showing use of the […]
Useful takeaways from this story.
The decision, by the European Commission, was based in large part on trial data showing use of the […]
Hopledo (IPX203), an extended-release formulation of levodopa and carbidopa sold as Crexont in the U.S., has now won approval in the European Union as a treatment for adults with Parkinson's disease who...
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
The decision, by the European Commission, was based in large part on trial data showing use of the […] Hopledo (IPX203), an extended-release formulation of levodopa and carbidopa sold as Crexont in the U.S., has now won approval in the European Union as a treatment for adults with Parkinson's disease who experience motor fluctuations despite medications.
Details worth keeping
Hopledo (IPX203), an extended-release formulation of levodopa and carbidopa sold as Crexont in the U.S., has now won approval in the European Union as a treatment for adults with Parkinson's disease who experience motor fluctuations despite medications.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.